Could this treatment free kidney patients from lifelong drugs?
NCT ID NCT04803006
Summary
This study tested a new approach to help kidney transplant recipients safely stop taking lifelong anti-rejection medications. It combined a special drug (siplizumab) with an infusion of cells from the kidney donor and mild chemotherapy. The goal was to find the best treatment plan to 'teach' the recipient's immune system to accept the new kidney without needing daily drugs. The trial was stopped early after enrolling only 4 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.